About: Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) article scientifique publié en 2005 (fr) наукова стаття, опублікована у вересні 2005 (uk) im September 2005 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57734267-12F077F4-2BBB-47C9-B191-9DD1A31EFEE0
publication date	2005-08-22 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57734267-83E4AF46-CE55-4EE2-95E2-B3562DF4F7B8
language of work or name	English
author name string	wds:Q57734267-24A0D10C-E361-492E-B6B9-BE794DD1C4BC wds:Q57734267-5EDF1F71-47C7-4A25-A6C4-2C54403143B9 wds:Q57734267-5FC4072B-9664-4FE6-A3B6-6824C3C6EBB0 wds:Q57734267-6DA065C2-015B-463D-A777-DC55D0B2A3D1 wds:Q57734267-84D00157-4CBC-4678-B58A-DDD0442E3075 wds:Q57734267-99031525-4C43-438F-A7EC-471C2B23EB67 wds:Q57734267-A9B443BE-6D41-4F31-8637-290094260468 wds:Q57734267-B6F85CFF-60D5-4B12-934B-82E29CF8FCDF wds:Q57734267-D9B926D7-6D22-4681-B03A-A7BCB46352E8
author name string	Shimada H Matthay KK Look AT Thorner P Seeger RC Castleberry RP Maris JM Brodeur G London WB
rdfs:label	Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (en) Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (nl)
skos:prefLabel	Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (en) Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (nl)
name	Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (en) Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group (nl)
author	wds:Q57734267-EA3A208E-57AE-4094-A702-CA719148ADBD wds:Q57734267-F1B7C7F6-71E7-4382-BA75-273752211AB3
author	Susan L. Cohn C P Reynolds
title	wds:Q57734267-22041621-D817-4B2A-8DC3-4C9765828927
title	Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (en)
page(s)	wds:Q57734267-445760F5-39C9-4134-A3A6-98C8C61A9EB5
page(s)	6459-6465
instance of	wds:Q57734267-4A556FE2-05F2-4ABA-990A-2A2FF38B0785
instance of	scholarly article
main subject	wds:Q57734267-AA95AAA0-E400-4777-8D75-3E4460B37AB6
main subject	neuroblastoma
PubMed ID	wds:Q57734267-AAB7C649-D054-4540-AD77-32D3488CA479
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16116153
PubMed ID	16116153
published in	wds:Q57734267-01E92801-6874-486F-9B86-0D7D300CFE38
published in	Journal of Clinical Oncology
issue	wds:Q57734267-B70551F1-0AF9-49E5-9DF7-642062CD0F6F
volume	wds:Q57734267-648122A5-C26A-4B4D-B772-5A23A725D3A7
issue	27
volume	23
DOI	wds:Q57734267-010A5728-CFC4-4A0F-A4D7-302BF9BB1245
DOI	http://dx.doi.org/10.1200/JCO.2005.05.571
DOI	10.1200/JCO.2005.05.571
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57734267
is cites work of	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification Neuroblastoma Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study Systems biology and modeling in neuroblastoma: practicalities and perspectives Neuroblastoma: molecular pathogenesis and therapy Children's Oncology Group's 2013 blueprint for research: neuroblastoma MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma Recent advances in neuroblastoma Neuroblastoma: biology and staging Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data Two independent epigenetic biomarkers predict survival in neuroblastoma Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. New prognostic markers in neuroblastoma. Neuroblastoma in adolescents: genetic and clinical characterisation Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy Recent insights into the biology of neuroblastoma Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics Distinct signatures of the immune responses in low risk versus high risk neuroblastoma Development of treatment strategies for advanced neuroblastoma 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures The survival of osteosarcoma patients 10 years old or younger is not worse than the survival of older patients: a retrospective analysis Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients Immunology and immunotherapy of neuroblastoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software